Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Månatlig övervakning av plasma NfL hos behandlad återkommande-remitterande multipel skleros för att upptäcka ihållande infraklinisk sjukdomsaktivitet (MoMo-NfL)

2 november 2026 uppdaterad av: Centre Hospitalier Universitaire de Nīmes

Månatlig övervakning av plasma NfL vid behandlad RRMS för att upptäcka ihållande infraklinsk sjukdomsaktivitet

Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity. When monitoring treatment response in patients treated with disease modifying treatments (DMTs), the measurement of new or enlarging T2/FLAIR hyperintense lesions (NELs) is the preferred MRI method supplemented by contrast-enhancing lesions (CELs) for monitoring treatment response. However, some studies have suggested the deposition of gadolinium-based contrast agents in the basal ganglia and dentate nucleus of patients who underwent serial MRI acquisitions. Although significant clinical consequences of these deposits have not been demonstrated, further studies are required to better understand the potential long-term biological and clinical effects of gadolinium administration. To circumvent this potential risk, several recommendations suggested avoiding unnecessary use of gadolinium for follow-up scans. New sequences are also developed to replace gadolinium injection for the detection of active lesions. Moreover, MRI remains costly and time-consuming. In addition, systematic yearly MRI monitoring is not adapted to detect silent active lesions. This can delay identification of treatment failure and increase the risk of relapses and disability worsening, especially in the context of escalation therapy.

Therefore, biological markers could allow more frequent analysis of disease activity and detect treatment failure earlier than classical clinical and MRI monitoring. Their use would greatly help clinicians to switch for high efficacy treatments (HET) and avoid potential relapses.

Measurement of a structural axonal protein, neurofilament, in serum or plasma has shown promise as a marker of neuroaxonal injury and a measure of treatment response. In MS, cerebrospinal fluid (CSF) neurofilament-light chain (NfL) is also increased and is positively associated with MRI lesion load and disability scores and is a marker of treatment response.

WThe study authors hypothesize that monthly plasma neurofilament-light chain (pNfL) monitoring can sensitively highlight subclinical (radiological disease activity) RDA by performing early MRI scans to confirm EDA and lead to timely treatment escalation.

The main objective of this study is to compare the time to EDA in both arms (monthly pNfL monitoring vs. standard care with regular MRI scans), in patients with EDA.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

84

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Montpellier, Frankrike, 34295
        • Rekrytering
        • CHU de Montpellier - Hôpital Guy de Chauliac
        • Kontakt:
      • Nantes, Frankrike, 44000
        • Har inte rekryterat ännu
        • CHU de Nantes
        • Kontakt:
      • Nice, Frankrike
      • Nîmes, Frankrike
        • Rekrytering
        • CHU de Nîmes
        • Kontakt:
      • Paris, Frankrike, 75013
        • Rekrytering
        • AP-HP, Hôpital de la Pitié Salpêtrière
        • Kontakt:
      • Rennes, Frankrike
        • Har inte rekryterat ännu
        • CHU de Rennes
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 55 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patient with RRMS according to 2024 McDonald's criteria.
  • Less than 10 years from disease onset.
  • Active RRMS (EDA) observed during the last 24 months: relapse and/or NELs and/or CELs as compared to a previous MRI performed within 24 months (± 3 months).
  • Current MET (IFN, GA, TE, fumarates) for less than 24 months.
  • Standard MRI follow-up scan performed less than 90 days before inclusion.
  • Clinically stable disease for at least 30 days.
  • Patients included in observational studies and cohorts (OFSEP, PROMISE …) will be eligible for inclusion in MoMo-NfL.
  • For women with reproductive potential: negative pregnancy test at the time of inclusion and use of an effective method to avoid pregnancy for the duration of the trial.
  • Patients able to adhere to the study visit schedule.
  • Patient must have signed and given the consent.
  • Patient affiliated or beneficiary of a health insurance plan.

Exclusion Criteria:

  • Pregnant or breastfeeding woman.
  • Patient unable to perform brain and/or spinal cord MRI scans.
  • Patient not willing to perform monthly blood punctures.
  • Patient treated with HET (S1P agonists, natalizumab, ocrelizumab, ofatumumab, rituximab, alemtuzumab, cladribine, mitoxantrone).
  • Patient with a relapse within 6 months before inclusion.
  • Patient with CELs within 3 months before inclusion.
  • Patient with progressive MS.
  • Patient unable to sign the consent.
  • It is impossible to correctly inform the patient.
  • Patient already participating in therapeutic research or in an exclusion period. The exclusion period corresponds to five half-lives (t1/2) of the experimental drug.
  • Patient under judicial protection, or is an adult under guardianship.
  • Female patients who are pregnant or breastfeeding or of reproductive potential who are not willing to employ effective birth control for the duration of the trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: Standardvård
Experimentell: pNfL-övervakningsgrupp

Monthly pNfL monitoring from blood samples. In case of >50% pNfL increase as compared to the mean of the 2 previous measures, an unscheduled visit with brain and spinal cord MRI will be scheduled

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Time to evidence of disease activity between groups
Tidsram: week 48

As assessed by new relapse and/or occurrence of NELs and/or CELs on a follow-up MRI scan

week 48
Time to evidence of disease activity between groups
Tidsram: week 96

As assessed by new relapse and/or occurrence of NELs and/or CELs on a follow-up MRI scan

week 96

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of CELs between groups
Tidsram: week 48

percent of active (contrast-enhancing) lesion

week 48
Proportion of CELs between groups
Tidsram: week 96

percent of active (contrast-enhancing) lesion

week 96
Rate of clinical relapses between groups
Tidsram: week 48

percentage patients experiencing relapse

week 48
Rate of clinical relapses between groups
Tidsram: week 96

percentage patients experiencing relapse

week 96
Time to switch to high efficacy treatments
Tidsram: week 48

Days

week 48
Time to switch to high efficacy treatments
Tidsram: week 96

Days

week 96
Proportion of patients switching to high efficacy treatments between groups
Tidsram: week 48

Percentage

week 48
Proportion of patients switching to high efficacy treatments between groups
Tidsram: week 96

Percentage

week 96
Change in pNfL levels in patients experiencing relapse with active MRI in experimental group
Tidsram: Upon experiencing relapse (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing relapse (maximum week 96)
Change in pNfL levels in patients experiencing acute clinical event in experimental group
Tidsram: Upon experiencing an acute clinical event (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing an acute clinical event (maximum week 96)
Change in pNfL levels in patients experiencing radiological disease activity without clinical symptoms in experimental group
Tidsram: Upon experiencing radiological disease activity (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon experiencing radiological disease activity (maximum week 96)
Change in pNfL levels in patients switching to high efficacy treatments
Tidsram: Upon evidence of disease activity (maximum week 96)

pg/mL; measured using Lumipulse® G NfL Blood

Upon evidence of disease activity (maximum week 96)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
To estimate the best threshold of pNfL increase (last measure as compared to the mean of 2 previous measures) with best accuracy to detect evidence of disease activity
Tidsram: week 96

pNfL levels in pg/mL

week 96
Time to evidence of disease activity using optimized threshold in experimental group
Tidsram: week 96

Months

week 96
Correlation between basal pNfL fluctuations in patients with no evidence of disease activity and brain health questionnaire score
Tidsram: week 96

Brain-Q

week 96
Description of adverse events
Tidsram: week 96

Descriptive

week 96
Level of disability
Tidsram: Baseline (Day 0)

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

Baseline (Day 0)
Level of disability
Tidsram: Week 48

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

Week 48
Level of disability
Tidsram: week 96

EDSS (Extanded Disability Status Scale) score, range: 0.0-10

week 96
Information processing speed impairment
Tidsram: Baseline (Day 0)

CSCT (Computerized Speed Cognitive Test): score and standard deviation

Baseline (Day 0)
Information processing speed impairment
Tidsram: week 48

CSCT (Computerized Speed Cognitive Test): score and standard deviation

week 48
Information processing speed impairment
Tidsram: week 96

CSCT (Computerized Speed Cognitive Test): score and standard deviation

week 96
Manual dexterity
Tidsram: Baseline (Day 0)

NHPT (Nine Hole Peg Test): time (seconds)

Baseline (Day 0)
Manual dexterity
Tidsram: week 48

NHPT (Nine Hole Peg Test): time (seconds)

week 48
Manual dexterity
Tidsram: week 96

NHPT (Nine Hole Peg Test): time (seconds)

week 96
Walking function
Tidsram: Baseline (Day 0)

T25FW (Timed 25-Foot Walk); time (seconds)

Baseline (Day 0)
Walking function
Tidsram: week 48

T25FW (Timed 25-Foot Walk); time (seconds)

week 48
Walking function
Tidsram: week 96

T25FW (Timed 25-Foot Walk); time (seconds)

week 96
Patient-reported change in status
Tidsram: Baseline (Day 0)

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

Baseline (Day 0)
Patient-reported change in status
Tidsram: Week 48

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

Week 48
Patient-reported change in status
Tidsram: week 96

PGIC (Patient Global Impression of Change scale): score (7 points Likert scale)

week 96
Patient-reported quality of life
Tidsram: Baseline (Day 0)

EQ-5D-5L score (0-100)

Baseline (Day 0)
Patient-reported quality of life
Tidsram: week 48

EQ-5D-5L score (0-100)

week 48
Patient-reported quality of life
Tidsram: week 96

EQ-5D-5L score (0-100)

week 96

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Eric Thouvenot, Centre Hospitalier Universitaire de Nīmes

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 december 2025

Primärt slutförande (Beräknad)

1 december 2030

Avslutad studie (Beräknad)

1 december 2030

Studieregistreringsdatum

Först inskickad

5 december 2025

Först inskickad som uppfyllde QC-kriterierna

5 december 2025

Första postat (Faktisk)

18 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera